Oroxat50 mg

Oroxat 50 mg is indicated for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).

The appropriate dose of Oroxat 50 mg must be taken orally three times per week and not on consecutive days. The dose should be individualized to achieve and maintain target Hb levels of 10 to 12 g/dL as described below:Patients not on erythropoiesis-stimulating agent treatment: For adults, the usual starting dose is 50 mg three times weekly. The recommended starting dose of Oroxat 50 mg is 70 mg three times per week in patients weighing less than 100 kg and 100 mg three times per week in patients weighing 100 kg and over.Patients switching from erythropoiesis-stimulating agents: For adults, the usual starting dose is 70 or 100mg three times weekly. The dosage thereafter should be adjusted according to the patient's condition.Dose adjustment: When dose adjustments are required, increase or decrease the dose according to the "Dose increase/decrease table" and "stepwise Dose adjustment sequence" below. Once adjusted, maintain the dose level for ≥4 weeks. If the hemoglobin concentration increases rapidly (>2.0 g/dL) within 4 weeks of a dose increase, decrease the dose or suspend the treatment immediately.The stepwise dose adjustments up or down should follow the sequence of the available doses: 20 mg-40 mg-50 mg-70 mg-100 mg-150 mg-200 mg-250 mg-300 mg-400 mg (only for CKD patients on dialysis).Missed dose: When there is ≥ 24-hour interval until the next scheduled dosing time, take the missed dose immediately and follow the prescribed schedule for subsequent doses. If there is <24 hours until the next scheduled dosing time, skip the missed dose, and take the next dose as scheduled. Do not take 2 doses on the same day.Method of administration: Oroxat 50 mg tablets are to be taken orally with or without food.

Oroxat 50 mg in combination with other medications may have drug-drug interaction.Oroxat 50 mg with Phosphate binders and other products containing multivalent cation (EXCEPT) lanthanum carbonate: Risk: decreased Oroxat 50 mg AUC by 67% and 46% and Cmax by 66% and 52% Recommendation: Oroxat 50 mg should be taken at least 1 hour after administration of phosphate binders or other medicinal products or supplements containing multivalent cations. Oroxat 50 mg with gemfbrozil (CYP2C8 and OATP1B1inhibitor) or probenecid (UGT and OAT1/OAT3 inhibitor) Risk: increased Oroxat 50 mg AUC by 2.3- fold and Cmax by 1.4-fold Recommendation: Adjust the dose of Oroxat 50 mg following dose adjustment rules based on Hb monitoring. Oroxat 50 mg with OATP1B1 or BCRP Substrates (simvastatin, rosuvastatin & atorvastatin) Risk: AUC and Cmax increased Recommendation: Adjust the dose of Oroxat 50 mg following dose adjustment rules based on Hb monitoring.

The common adverse reactions associated with Oroxat 50 mg are hypertension, vascular access thrombosis, diarrhoea, peripheral oedema, hyperkalaemia and nausea.

Oroxat 50 mg tablets should be used in caution. It may initiate few thrombotic vascular events (TVEs) particularly in patients with pre-existing risk factors for TVE, including obesity and prior history of TVEs. Oroxat 50 mg should be used with caution in patients with a history of seizures. Oroxat 50 mg should not be administered if the patient has serious signs and symptoms of an infection. Oroxat 50 mg should not be administered if the patient has liver disorder. Oroxat 50 mg should not be initiated in pregnant women.

Symptoms: When this drug was administered 5 mg/kg (510 mg) to a single healthy adult, increased heart rate transient have been reported. Hemoglobin concentration by overdosage of this drug is likely to increase more than necessary.Treatment: Appropriate measures of dose reduction or interruption, etc. of this drug. This drug is not removed by dialysis.

Store in a cool (below 30°C), dry place, away from light and moisture. Keep out of the reach of children.

Drugs for Haemolytic Hypoplastic & Renal Anemia

Oroxat 50 mg is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with potential anti-anemic activity. Upon administration, Oroxat 50 mg binds to and inhibits HIF-PH, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. Administration of Oroxat 50 mg has been shown to induce coordinated erythropoiesis, increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range, in multiple subpopulations of CKD patients, including in the presence of infammation, and without a need for supplemental intravenous iron.Oroxat 50 mg reversibly binds to and potently inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase enzymes, reducing HIF-α breakdown and promoting HIF transcriptional activity. Activation of the HIF pathway in this manner results in the induction of target genes involved in erythropoiesis, such as those for EPO, EPO receptor, proteins promoting iron absorption, iron transport and haem synthesis. Oroxat 50 mg dose-dependently increased haemoglobin (Hb) levels, signifcantly reduced hepcidin levels and transiently increased endogenous EPO levels within or near physiological range in patients with anemia of CKD who were not dialysis dependent. Oroxat 50 mg reduced the dysregulation of iron metabolism associated with CKD by increasing serum transferrin, intestinal iron absorption and the release of stored iron in a dose-dependent manner in patients with anemia associated with dialysis dependent or dialysis-independent CKD. Cholesterol levels were also signifcantly reduced from baseline with Oroxat 50 mg, regardless of the use of statins or other lipid-lowering agents.

Do not administered to women that may be pregnant or pregnant. Oroxat 50 mg is contraindicated during breast-feeding.

Children: Oroxat 50 mg is not indicated in children.liver dysfunction patients: Oroxat 50 mg is not recommended for use in patients with severe hepatic impairment.